Literature DB >> 10799756

Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.

H Q Wu1, P Guidetti, J H Goodman, M Varasi, G Ceresoli-Borroni, C Speciale, H E Scharfman, R Schwarcz.   

Abstract

Competing enzymatic mechanisms degrade the tryptophan metabolite L-kynurenine to kynurenate, an inhibitory and neuroprotective compound, and to the neurotoxins 3-hydroxykynurenine and quinolinate. Kynurenine 3-hydroxylase inhibitors such as PNU 156561 shift metabolism towards enhanced kynurenate production, and this effect may underlie the recently discovered anticonvulsant and neuroprotective efficacy of these drugs. Using electrophysiological and neurotoxicological endpoints, we now used PNU 156561 as a tool to examine the functional interplay of kynurenate, 3-hydroxykynurenine and quinolinate in the rat hippocampus in vivo. First, population spike amplitude in area CA1 and the extent of quinolinate-induced excitotoxic neurodegeneration were studied in animals receiving acute or prolonged intravenous infusions of L-kynurenine, PNU 156561, (L-kynurenine+PNU 156561) or kynurenate. Only the latter two treatments, but not L-kynurenine or PNU 156561 alone, caused substantial inhibition of evoked responses in area CA1, and only prolonged (3h) infusion of (L-kynurenine+PNU 156561) or kynurenate was neuroprotective. Biochemical analyses in separate animals revealed that the levels of kynurenate attained in both blood and brain (hippocampus) were essentially identical in rats receiving extended infusions of L-kynurenine alone or (L-kynurenine+PNU 156561) (4 and 7microM, respectively, after an infusion of 90 or 180min). However, addition of the kynurenine 3-hydroxylase inhibitor resulted in a significant decrement in the formation of 3-hydroxykynurenine and quinolinate in both blood and brain. These data suggest that the ratio between kynurenate and 3-hydroxykynurenine and/or quinolinate in the brain is a critical determinant of neuronal excitability and viability. The anticonvulsant and neuroprotective potency of kynurenine 3-hydroxylase inhibitors may therefore be due to the drugs' dual action on both branches of the kynurenine pathway of tryptophan degradation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799756     DOI: 10.1016/s0306-4522(00)00030-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

1.  Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.

Authors:  Claudia Di Serio; Andrea Cozzi; Ilaria Angeli; Laura Doria; Isabella Micucci; Silvia Pellerito; Patrizia Mirone; Giulio Masotti; Flavio Moroni; Francesca Tarantini
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

2.  Behavioural studies with a newly developed neuroprotective KYNA-amide.

Authors:  Levente Gellért; Dániel Varga; Marian Ruszka; József Toldi; Tamás Farkas; István Szatmári; Ferenc Fülöp; László Vécsei; Zsolt Kis
Journal:  J Neural Transm (Vienna)       Date:  2011-08-05       Impact factor: 3.575

3.  Elevations of endogenous kynurenic acid produce spatial working memory deficits.

Authors:  Amy C Chess; Michael K Simoni; Torey E Alling; David J Bucci
Journal:  Schizophr Bull       Date:  2006-08-18       Impact factor: 9.306

4.  Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats.

Authors:  Katelyn V Trecartin; David J Bucci
Journal:  Schizophr Res       Date:  2011-09-09       Impact factor: 4.939

5.  Targeted plasma metabolome response to variations in dietary glycemic load in a randomized, controlled, crossover feeding trial in healthy adults.

Authors:  Sally Barton; Sandi L Navarro; Matthew F Buas; Yvonne Schwarz; Haiwei Gu; Danijel Djukovic; Daniel Raftery; Mario Kratz; Marian L Neuhouser; Johanna W Lampe
Journal:  Food Funct       Date:  2015-09       Impact factor: 5.396

Review 6.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Analysis of the wild-type and mutant genes encoding the enzyme kynurenine monooxygenase of the yellow fever mosquito, Aedes aegypti.

Authors:  Q Han; E Calvo; O Marinotti; J Fang; M Rizzi; A A James; J Li
Journal:  Insect Mol Biol       Date:  2003-10       Impact factor: 3.585

8.  5-Hydroxyanthranilic acid, a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones.

Authors:  Andrew J Smith; Robert A Smith; Trevor W Stone
Journal:  Neurotox Res       Date:  2009-03-04       Impact factor: 3.911

Review 9.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

10.  The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.

Authors:  Marieke C Wichers; Michael Maes
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.